Childhood CancerZERO2NCT05504772
Precision Medicine for Every Child With Cancer
An observational study of Childhood Cancer and Childhood Solid Tumor, run by Australian & New Zealand Children's Haematology/Oncology Group at 11 sites in 2 countries.
Trial summary
To improve outcomes for childhood cancer patients through the implementation of precision medicine. Read more about this study
- Who is it for?
- Ages 0 to 25 years
- Conditions the study is for
- Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor
- What is being tested?
- Whole Genome Sequencing, RNA seq and DNA Methylation
- How many people
- 3,500 participants
- Where
- 11 sitesin 2 countries
- Study dates
- 16 Dec 2022to Jul 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 25 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Patients <18 years of age with a diagnosis of tumor or cancer Patients aged 19 - 25 years with a diagnosis of a pediatric tumor or cancer
Who may be able to join
- Age < 18 years Note: Individual patients aged 19 - 25 years old with a pediatric cancer, e.g., neuroblastoma, may be enrolled after discussion with, and at the discretion of, the Study Chair or their delegate.
- Life expectancy >6 weeks at time of enrolment
- Consent i. Signed and dated informed consent for study enrolment from participant aged ≥ 18 years or from parent/guardian of participant aged <18 years. ii. Separate signed and dated informed consent for understanding the role of germline testing and choice for the return of germline results.
Who cannot join
None listed.
Trial locations and contacts
11 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
11 sites in 2 countries
Australia9 sites, 9 recruiting
- Recruiting
Women's and Children's Hospital
Adelaide
Suzanne Milne, suzanne.milne@sa.gov.au
- Recruiting
Queensland Children's Hospital
Brisbane
Natasha Brown, natasha.brown@health.qld.gov.au
- Recruiting
Royal Hobart Hospital
Hobart
David Nolan, david.nolan@ths.tas.gov.au
- Recruiting
Monash Children's Hospital
Melbourne
Amanda St John, Amanda.StJohn@monashhealth.org
- Recruiting
Royal Children's Hospital
Melbourne
Kahlia Fox, clinicaltrialsmanager@rch.org.au
- Recruiting
John Hunter Children's Hospital
Newcastle
Rebecca Jensen, Rebecca.Jensen@health.nsw.gov.au
- Recruiting
Perth Children's Hospital
Perth
Jennifer McConnell, jennifer.mcconnell@health.wa.gov.au
- Recruiting
Sydney Children's Hospital, Randwick
Sydney
Sandra Montez, Sandra.Montez@health.nsw.gov.au
- Recruiting
The Children's Hospital at Westmead
Sydney
Jun Christian, jun.christian@health.nsw.gov.au
New Zealand2 sites, 2 recruiting
- Recruiting
Starship Children's Hospital
Auckland, Grafton, 1023
Sarah Hunter, SHunter@adhb.govt.nz
- Not yet recruiting
Christchurch Hospital
Christchurch, 8011
Kirstie Copeland, Kirstie.copeland@cdhb.health.nz
About this study
To improve outcomes for childhood cancer patients through the implementation of precision medicine.
Read the detailed description
Through the pilot TARGET and national PRISM trials the feasibility and benefits of using comprehensive molecular profiling and preclinical drug testing in real time for high-risk (HR) patients has been demonstrated. However, the role of precision medicine, especially in facilitating diagnosis and risk stratification in non-HR childhood cancers has not been studied. Integrative tumor-germline whole genome sequencing (WGS) analysis has the potential to advance our understanding of cancer predisposition. In this study, the ZERO platform will be extended to all children with cancer in Australia and New Zealand, evaluating the benefits of precision medicine in different childhood cancer types and risk groups.
- Conditions
- Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Childhood Leukemia, Refractory Cancer, Relapsed Cancer
- Being tested
- Whole Genome Sequencing, RNA seq, DNA Methylation, Targeted Panel Sequencing, High Throughput Sequencing (in vitro)
- Keywords
- children, precision medicine, personalised medicine, molecular profiling, pediatric, paediatric
- Medical subject headings
- Neoplasms, Recurrence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Whole Genome SequencingGenetic
Each tumor sample will be sequenced and analyzed in parallel with its matched normal (germline DNA from the same patient) to enable the identification of somatic aberrations.
RNA seqGenetic
Results will be used for bioinformatics analysis for fusion transcripts and gene expression.
DNA MethylationGenetic
Genome-wide assessment of DNA methylation will be conducted on all samples where possible.
Targeted Panel SequencingGenetic
Targeted panel sequencing may be performed:
- When WGS is not feasible or appropriate, e.g., insufficient DNA from fresh or frozen sample or only Formalin-Fixed Paraffin-Embedded (FFPE) material is available
- When mosaicism is suspected
- When indicated for a disease type
High Throughput Sequencing (in vitro)Genetic
High throughput drug screening will be attempted for tumors from Cohort 1 (high-risk cancers with survival <30%) and selected tumor types.
Patient Derived Xenograft (PDX)(in vivo)Genetic
In vivo drug testing in patient derived xenograft (PDX) will be attempted for tumors from Cohort 1 (high-risk cancers) and selected tumor types.
Liquid BiopsyOther
Liquid biopsy will be investigated as a non-invasive method for diagnosis of tumors that are difficult to biopsy directly, understanding tumor heterogeneity, monitoring of treatment response, and detection of minimal residual disease (MRD)/relapse in leukemia, solid and CNS tumors.
| Study group | Role | What they receive |
|---|---|---|
| High-risk cancers | One of the following two criteria must be met:
1. Confirmed or suspected high-risk malignancy defined as expected overall survival < 30% based on current literature for the specific cancer
2. Cancers for which standard therapy would result in unacceptable and severe morbidity (e.g., infantile fibrosarcoma where definitive surgery would require amputation of limb) Note: This does not include HR neuroblastoma at diagnosis as this group of patients have an overall survival ≥30% and belongs to Cohort 4A. Receives: Genetic: Whole Genome Sequencing; Genetic: RNA seq; Genetic: DNA Methylation; Genetic: Targeted Panel Sequencing; Genetic: High Throughput Sequencing (in vitro); Genetic: Patient Derived Xenograft (PDX)(in vivo); Other: Liquid Biopsy | |
| Rare tumors | At least one of the following three criteria must be met:
1. A rare tumor of uncertain prognosis due to rarity of disease
2. A rare tumor with no established treatment strategy
3. A cancer where routine histopathological examination has not been able to establish a diagnosis
4. Confirmed histiocytic disorder AND molecular profiling may facilitate diagnosis and/or treatment
5. Confirmed proliferative vascular or lymphatic malformation AND has failed conventional treatment, e.g., surgery or embolization, OR no appropriate treatment is available AND the disease is organ, limb or life threatening, or debilitating Receives: Genetic: Whole Genome Sequencing; Genetic: RNA seq; Genetic: DNA Methylation; Genetic: Targeted Panel Sequencing; Other: Liquid Biopsy | |
| Primary central nervous system (CNS) tumours | Patient is suspected or confirmed to have a primary CNS tumor, including low and high-grade tumors Receives: Genetic: Whole Genome Sequencing; Genetic: RNA seq; Genetic: DNA Methylation; Genetic: Targeted Panel Sequencing; Other: Liquid Biopsy | |
| Neuroblastoma | Patient is suspected or confirmed to have neuroblastoma 4A: HR neuroblastoma at diagnosis 4B: Non-HR neuroblastoma Receives: Genetic: Whole Genome Sequencing; Genetic: RNA seq; Genetic: DNA Methylation; Genetic: Targeted Panel Sequencing; Other: Liquid Biopsy | |
| Acute myeloid leukemia, myelodysplastic syndrome and other leukemias not classified as ALL | Patient is confirmed by flow cytometry to have acute myeloid leukemia (AML) or other leukemias (Note: Verbal confirmation of flow cytometry result is adequate for enrolment) Receives: Genetic: Whole Genome Sequencing; Genetic: RNA seq; Genetic: DNA Methylation; Genetic: Targeted Panel Sequencing; Other: Liquid Biopsy | |
| Acute lymphoblastic leukemia (ALL) | Patient is confirmed to have acute lymphoblastic leukemia by flow cytometry (Note: Verbal confirmation of flow cytometry result is adequate for enrolment) Receives: Genetic: Whole Genome Sequencing; Genetic: RNA seq; Genetic: DNA Methylation; Genetic: Targeted Panel Sequencing; Other: Liquid Biopsy | |
| Lymphomas | Patient is suspected or confirmed to have a lymphoma Receives: Genetic: Whole Genome Sequencing; Genetic: RNA seq; Genetic: DNA Methylation; Genetic: Targeted Panel Sequencing; Other: Liquid Biopsy | |
| Sarcomas | Patient is suspected or confirmed to have a sarcoma Includes gastrointestinal stromal tumour (GIST), malignant peripheral nerve sheath tumour (MPNST), desmoplastic small round cell tumour (DSRCT) Receives: Genetic: Whole Genome Sequencing; Genetic: RNA seq; Genetic: DNA Methylation; Genetic: Targeted Panel Sequencing; Other: Liquid Biopsy | |
| Renal tumors | Patient is suspected or confirmed to have a renal tumor Includes clear cell sarcoma of kidney Receives: Genetic: Whole Genome Sequencing; Genetic: RNA seq; Genetic: DNA Methylation; Genetic: Targeted Panel Sequencing; Other: Liquid Biopsy | |
| Hepatic and biliary tree tumors | Patient is suspected or confirmed to have a liver or biliary tree tumor Receives: Genetic: Whole Genome Sequencing; Genetic: RNA seq; Genetic: DNA Methylation; Genetic: Targeted Panel Sequencing; Other: Liquid Biopsy | |
| Thyroid and endocrine tumors | Patient is suspected or confirmed to have a thyroid or endocrine cancer Receives: Genetic: Whole Genome Sequencing; Genetic: RNA seq; Genetic: DNA Methylation; Genetic: Targeted Panel Sequencing; Other: Liquid Biopsy | |
| Other tumors | Patient is suspected or confirmed to have a tumor which does not fit into any of the above Receives: Genetic: Whole Genome Sequencing; Genetic: RNA seq; Genetic: DNA Methylation; Genetic: Targeted Panel Sequencing; Other: Liquid Biopsy | |
| Germline only | One of the following two criteria must be met:
1. Patients whose submitted tumor sample could not yield sufficient DNA for any molecular analysis AND participants/parents have consented to return of germline findings.
2. Patients who do not have appropriate tumor sample to be submitted for molecular profiling may be considered for germline only analysis. Obtaining tumor samples wherever possible will be encouraged. Receives: Genetic: Whole Genome Sequencing; Genetic: RNA seq; Genetic: DNA Methylation; Genetic: Targeted Panel Sequencing; Other: Liquid Biopsy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Utility of recommended personalized therapy for HR childhood cancer patients.
Disease control rate (stable disease + partial response + complete response) in HR patients who have received recommended personalized therapy which are molecularly and/or preclinically directed
Measured: 5 years
Utility of recommended personalized therapy for non-HR childhood cancer patients.
The proportion of non-HR patients for whom the disease specific, clinically relevant, virtual molecular panel provides additional or equivalent results for diagnosis and risk stratification when compared with routine diagnostic tests.
Measured: 5 years
Secondary outcomes (6)
Utility of pre-defined virtual molecular panel for non-HR childhood cancer patients.
The proportion of non-HR patients for whom a pre-defined virtual molecular panel; leads to a streamline molecular report issued within 4 weeks from receipt of samples, changes or refines the initial histopathological diagnosis, changes or refines risk stratification at diagnosis, changes or refines treatment at diagnosis and/or facilitates enrolment in clinical trials requiring prior molecular studies.
Measured: 5 years
Utility of comprehensive precision medicine for patients with rare tumors in childhood.
Proportion of rare cancer cohort patients for which comprehensive precision medicine improves diagnosis, identifies at least one therapeutic target or facilitates improvement in therapy within a clinically relevant timeframe.
Measured: 5 years
Utility of Molecular Tumour Board (MTB) recommendation tier system for HR childhood cancer patients.
Evaluation of the correlation of MTB recommendation tier to treatment outcome, clinician rated value of MTB recommendation tier in facilitating therapeutic decision and drug access and proportion of HR patients for which the MTB recommendation improves diagnosis, risk stratification or facilitates improvement in therapy within a clinically relevant timeframe.
Measured: 5 years
Utility of preclinical testing in HR childhood cancer patients.
Evaluation of proportion of tumors where in vitro sensitivity testing can be successfully performed compared with PRISM trial, turnaround time for preclinical in vitro and in vivo drug testing, proportion of tumors where in vitro drug sensitivity identifies additional molecular drivers and proportion of patients for whom preclinical testing:
- Facilitates therapeutic decision ii. Identifies additional therapeutic options in patients for whom genomic profiling did not identify molecular targets iii. Predicts clinical outcome
Measured: 5 years
Clinical utility of germline WGS in patients with childhood cancers.
Evaluation of;
- Proportion of HR and non-HR patients with a reportable germline finding (i. For whom the result was not previously known ii. For whom the results would have been missed using current clinical testing criteria)
- Proportion of patients for whom medical management for the current cancer and future cancer risk has been altered based on the germline findings
Measured: 5 years
Treatment outcome in HR childhood cancer patients who have received recommended personalised therapy which are molecularly and/or preclinically directed.
Evaluation of;
- Objective response in patients who have received single agent versus combination personalized therapy
- Disease control (stable disease + partial response + complete response) in patients who have received a single agent versus combination personalized therapy
- Progression-free interval (PFI) ratio: PFI personalized therapy : PFI conventional therapy
- Difference in outcome between patients have received recommended personalised therapy and those who did not (i. Proportion of patients without progression or death at 6 and 12 months between the two groups ii. Difference in progression-free and overall survival between the two groups)
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2022
- Study start16 Dec 2022
- Primary completionJul 2025 (estimated)
- Study completionJul 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Childhood CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Australian & New Zealand Children's Haematology/Oncology Group
- Sponsor type
- University, hospital or other
- Collaborators
- Children's Cancer Institute (CCI), Minderoo Foundation, Medical Research Future Fund
- Responsible party
- Sponsor
- Investigators
- David Ziegler, Principal investigator, SCHN
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05504772
- Sponsor's protocol ID
- ZERO2
- Acronym
- ZERO2
- Status last verified
- Jul 2024
- First submitted
- 30 Jan 2022
- Last updated
- 17 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Precision Medicine for Every Child With Cancer
- ClinicalTrials.gov ID
- NCT05504772
- Acronym / sponsor ID
- ZERO2 / ZERO2
- Conditions
- Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Childhood Leukemia, Refractory Cancer, Relapsed Cancer
- Keywords
- children, precision medicine, personalised medicine, molecular profiling, pediatric, paediatric
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 3,500 participants (estimated)
- Lead sponsor
- Australian & New Zealand Children's Haematology/Oncology GroupUniversity, hospital or other
- Collaborators
- Children's Cancer Institute (CCI), Minderoo Foundation, Medical Research Future Fund
- Study start
- 16 Dec 2022 (actual)
- Primary completion
- Jul 2025 (estimated)
- Study completion
- Jul 2030 (estimated)
- First posted
- 17 Aug 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To improve outcomes for childhood cancer patients through the implementation of precision medicine.
Detailed description
Through the pilot TARGET and national PRISM trials the feasibility and benefits of using comprehensive molecular profiling and preclinical drug testing in real time for high-risk (HR) patients has been demonstrated. However, the role of precision medicine, especially in facilitating diagnosis and risk stratification in non-HR childhood cancers has not been studied. Integrative tumor-germline whole genome sequencing (WGS) analysis has the potential to advance our understanding of cancer predisposition. In this study, the ZERO platform will be extended to all children with cancer in Australia and New Zealand, evaluating the benefits of precision medicine in different childhood cancer types and risk groups.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 13
| Arm | Type | Receives |
|---|---|---|
| High-risk cancers | – | Genetic: Whole Genome Sequencing, Genetic: RNA seq, Genetic: DNA Methylation, Genetic: Targeted Panel Sequencing, Genetic: High Throughput Sequencing (in vitro), Genetic: Patient Derived Xenograft (PDX)(in vivo), Other: Liquid BiopsyOne of the following two criteria must be met: 1. Confirmed or suspected high-risk malignancy defined as expected overall survival < 30% based on current literature for the specific cancer 2. Cancers for which standard therapy would result in unacceptable and severe morbidity (e.g., infantile fibrosarcoma where definitive surgery would require amputation of limb) Note: This does not include HR neuroblastoma at diagnosis as this group of patients have an overall survival ≥30% and belongs to Cohort 4A. |
| Rare tumors | – | Genetic: Whole Genome Sequencing, Genetic: RNA seq, Genetic: DNA Methylation, Genetic: Targeted Panel Sequencing, Other: Liquid BiopsyAt least one of the following three criteria must be met: 1. A rare tumor of uncertain prognosis due to rarity of disease 2. A rare tumor with no established treatment strategy 3. A cancer where routine histopathological examination has not been able to establish a diagnosis 4. Confirmed histiocytic disorder AND molecular profiling may facilitate diagnosis and/or treatment 5. Confirmed proliferative vascular or lymphatic malformation AND has failed conventional treatment, e.g., surgery or embolization, OR no appropriate treatment is available AND the disease is organ, limb or life threatening, or debilitating |
| Primary central nervous system (CNS) tumours | – | Genetic: Whole Genome Sequencing, Genetic: RNA seq, Genetic: DNA Methylation, Genetic: Targeted Panel Sequencing, Other: Liquid BiopsyPatient is suspected or confirmed to have a primary CNS tumor, including low and high-grade tumors |
| Neuroblastoma | – | Genetic: Whole Genome Sequencing, Genetic: RNA seq, Genetic: DNA Methylation, Genetic: Targeted Panel Sequencing, Other: Liquid BiopsyPatient is suspected or confirmed to have neuroblastoma 4A: HR neuroblastoma at diagnosis 4B: Non-HR neuroblastoma |
| Acute myeloid leukemia, myelodysplastic syndrome and other leukemias not classified as ALL | – | Genetic: Whole Genome Sequencing, Genetic: RNA seq, Genetic: DNA Methylation, Genetic: Targeted Panel Sequencing, Other: Liquid BiopsyPatient is confirmed by flow cytometry to have acute myeloid leukemia (AML) or other leukemias (Note: Verbal confirmation of flow cytometry result is adequate for enrolment) |
| Acute lymphoblastic leukemia (ALL) | – | Genetic: Whole Genome Sequencing, Genetic: RNA seq, Genetic: DNA Methylation, Genetic: Targeted Panel Sequencing, Other: Liquid BiopsyPatient is confirmed to have acute lymphoblastic leukemia by flow cytometry (Note: Verbal confirmation of flow cytometry result is adequate for enrolment) |
| Lymphomas | – | Genetic: Whole Genome Sequencing, Genetic: RNA seq, Genetic: DNA Methylation, Genetic: Targeted Panel Sequencing, Other: Liquid BiopsyPatient is suspected or confirmed to have a lymphoma |
| Sarcomas | – | Genetic: Whole Genome Sequencing, Genetic: RNA seq, Genetic: DNA Methylation, Genetic: Targeted Panel Sequencing, Other: Liquid BiopsyPatient is suspected or confirmed to have a sarcoma Includes gastrointestinal stromal tumour (GIST), malignant peripheral nerve sheath tumour (MPNST), desmoplastic small round cell tumour (DSRCT) |
| Renal tumors | – | Genetic: Whole Genome Sequencing, Genetic: RNA seq, Genetic: DNA Methylation, Genetic: Targeted Panel Sequencing, Other: Liquid BiopsyPatient is suspected or confirmed to have a renal tumor Includes clear cell sarcoma of kidney |
| Hepatic and biliary tree tumors | – | Genetic: Whole Genome Sequencing, Genetic: RNA seq, Genetic: DNA Methylation, Genetic: Targeted Panel Sequencing, Other: Liquid BiopsyPatient is suspected or confirmed to have a liver or biliary tree tumor |
| Thyroid and endocrine tumors | – | Genetic: Whole Genome Sequencing, Genetic: RNA seq, Genetic: DNA Methylation, Genetic: Targeted Panel Sequencing, Other: Liquid BiopsyPatient is suspected or confirmed to have a thyroid or endocrine cancer |
| Other tumors | – | Genetic: Whole Genome Sequencing, Genetic: RNA seq, Genetic: DNA Methylation, Genetic: Targeted Panel Sequencing, Other: Liquid BiopsyPatient is suspected or confirmed to have a tumor which does not fit into any of the above |
| Germline only | – | Genetic: Whole Genome Sequencing, Genetic: RNA seq, Genetic: DNA Methylation, Genetic: Targeted Panel Sequencing, Other: Liquid BiopsyOne of the following two criteria must be met: 1. Patients whose submitted tumor sample could not yield sufficient DNA for any molecular analysis AND participants/parents have consented to return of germline findings. 2. Patients who do not have appropriate tumor sample to be submitted for molecular profiling may be considered for germline only analysis. Obtaining tumor samples wherever possible will be encouraged. |
Who may qualify
- Ages
- 0 to 25 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Patients <18 years of age with a diagnosis of tumor or cancer Patients aged 19 - 25 years with a diagnosis of a pediatric tumor or cancer
Key inclusion criteria (3 listed)
- Age < 18 years Note: Individual patients aged 19 - 25 years old with a pediatric cancer, e.g., neuroblastoma, may be enrolled after discussion with, and at the discretion of, the Study Chair or their delegate.
- Life expectancy >6 weeks at time of enrolment
- Consent i. Signed and dated informed consent for study enrolment from participant aged ≥ 18 years or from parent/guardian of participant aged <18 years. ii. Separate signed and dated informed consent for understanding the role of germline testing and choice for the return of germline results.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Whole Genome SequencingEach tumor sample will be sequenced and analyzed in parallel with its matched normal (germline DNA from the same patient) to enable the identification of somatic aberrations. | Genetic | Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia, myelodysplastic syndrome and other leukemias not classified as ALL, Germline only, Hepatic and biliary tree tumors, High-risk cancers, Lymphomas, Neuroblastoma, Other tumors, Primary central nervous system (CNS) tumours, Rare tumors, Renal tumors, Sarcomas, Thyroid and endocrine tumors |
| RNA seqResults will be used for bioinformatics analysis for fusion transcripts and gene expression. | Genetic | Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia, myelodysplastic syndrome and other leukemias not classified as ALL, Germline only, Hepatic and biliary tree tumors, High-risk cancers, Lymphomas, Neuroblastoma, Other tumors, Primary central nervous system (CNS) tumours, Rare tumors, Renal tumors, Sarcomas, Thyroid and endocrine tumors |
| DNA MethylationGenome-wide assessment of DNA methylation will be conducted on all samples where possible. | Genetic | Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia, myelodysplastic syndrome and other leukemias not classified as ALL, Germline only, Hepatic and biliary tree tumors, High-risk cancers, Lymphomas, Neuroblastoma, Other tumors, Primary central nervous system (CNS) tumours, Rare tumors, Renal tumors, Sarcomas, Thyroid and endocrine tumors |
| Targeted Panel SequencingTargeted panel sequencing may be performed: 1. When WGS is not feasible or appropriate, e.g., insufficient DNA from fresh or frozen sample or only Formalin-Fixed Paraffin-Embedded (FFPE) material is available 2. When mosaicism is suspected 3. When indicated for a disease type | Genetic | Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia, myelodysplastic syndrome and other leukemias not classified as ALL, Germline only, Hepatic and biliary tree tumors, High-risk cancers, Lymphomas, Neuroblastoma, Other tumors, Primary central nervous system (CNS) tumours, Rare tumors, Renal tumors, Sarcomas, Thyroid and endocrine tumors |
| High Throughput Sequencing (in vitro)High throughput drug screening will be attempted for tumors from Cohort 1 (high-risk cancers with survival <30%) and selected tumor types. | Genetic | High-risk cancers |
| Patient Derived Xenograft (PDX)(in vivo)In vivo drug testing in patient derived xenograft (PDX) will be attempted for tumors from Cohort 1 (high-risk cancers) and selected tumor types. | Genetic | High-risk cancers |
| Liquid BiopsyLiquid biopsy will be investigated as a non-invasive method for diagnosis of tumors that are difficult to biopsy directly, understanding tumor heterogeneity, monitoring of treatment response, and detection of minimal residual disease (MRD)/relapse in leukemia, solid and CNS tumors. | Other | Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia, myelodysplastic syndrome and other leukemias not classified as ALL, Germline only, Hepatic and biliary tree tumors, High-risk cancers, Lymphomas, Neuroblastoma, Other tumors, Primary central nervous system (CNS) tumours, Rare tumors, Renal tumors, Sarcomas, Thyroid and endocrine tumors |
Primary outcome
Utility of recommended personalized therapy for HR childhood cancer patients.
Time frame: 5 years
Disease control rate (stable disease + partial response + complete response) in HR patients who have received recommended personalized therapy which are molecularly and/or preclinically directed
Utility of recommended personalized therapy for non-HR childhood cancer patients.
Time frame: 5 years
The proportion of non-HR patients for whom the disease specific, clinically relevant, virtual molecular panel provides additional or equivalent results for diagnosis and risk stratification when compared with routine diagnostic tests.
6 secondary outcomes
Utility of pre-defined virtual molecular panel for non-HR childhood cancer patients.
Time frame: 5 years
Utility of comprehensive precision medicine for patients with rare tumors in childhood.
Time frame: 5 years
Utility of Molecular Tumour Board (MTB) recommendation tier system for HR childhood cancer patients.
Time frame: 5 years
Utility of preclinical testing in HR childhood cancer patients.
Time frame: 5 years
Clinical utility of germline WGS in patients with childhood cancers.
Time frame: 5 years
Treatment outcome in HR childhood cancer patients who have received recommended personalised therapy which are molecularly and/or preclinically directed.
Time frame: 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2024.
Related trials for Childhood Cancer
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
RecruitingObservational study
Psychological Benefits of a Normalized Camping Experience for Children With Cancer
Pediatric Cancer
Recruiting
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Solid Tumor, Adult, Solid Tumor, Childhood
RecruitingObservational study
The Decision To Enroll In Therapeutic Clinical Trials In A Pediatric Cancer Clinical Network
Knowledge, Attitudes, Practice
Recruiting
Facial Expression Awareness Training to Understand and Recognize Emotions
Survivors of Pediatric Brain Tumors, Pediatric Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
David Ziegler principal investigator
SCHN
11 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Childhood Cancer and Childhood Solid Tumor, run by Australian & New Zealand Children's Haematology/Oncology Group at 11 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 11 sites in Australia, New Zealand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact National Study Coordinator (+61 2 9382 3102, SCHN-ZERO2@health.nsw.gov.au), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Utility of recommended personalized therapy for HR childhood cancer patients. (time frame: 5 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2024.